Breaking News Instant updates and real-time market news.

EIDX

Eidos Therapeutics

$12.71

0.34 (2.75%)

13:11
11/11/18
11/11
13:11
11/11/18
13:11

Eidos Therapeutics announces positive Phase 2 data for AG10

Eidos Therapeutics announced positive results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin amyloidosis cardiomyopathy. The data were presented in a late-breaking Featured Science oral presentation at the American Heart Association Scientific Sessions. AG10 was well tolerated, demonstrated greater than 90% TTR average stabilization at day 28, and increased serum TTR concentrations, a prognostic indicator of survival in ATTR-CM, in a dose-dependent manner. Subject to discussions with regulatory agencies, these data support the advancement of AG10 into Phase 3 pivotal trials planned to be initiated in the first half of 2019. The study met its primary objective of establishing that AG10 was well tolerated with no safety signals of potential clinical concern related to the administration of AG10 in symptomatic ATTR-CM patients. One serious adverse event of dyspnea deemed unrelated to study drug was observed in one actively-treated subject and SAEs of atrial fibrillation, congestive heart failure, and cellulitis were observed in two placebo-treated subjects. The overall rate of adverse events was 69% in subjects administered 800 mg bid AG10, 63% in subjects administered 400 mg bid AG10, and 88% in subjects administered placebo. As compared to placebo, subjects treated with AG10 demonstrated a statistically significant increase in serum TTR concentrations, a prognostic indicator of survival in ATTR-CM patients, in a dose-dependent manner. Subjects administered 800 mg AG10 twice daily, 400 mg AG10 twice daily, and placebo exhibited mean changes in TTR concentration from baseline of +50%, +36% and -7%, respectively, at day 28. All subjects administered AG10 had serum TTR concentrations within the normal range at day 28, whereas 31% of subjects administered placebo had serum TTR concentrations below the normal range on day 28. AG10 administration resulted in near-complete stabilization of TTR at day 28, across the dosing interval in all actively treated subjects as measured by established ex vivo assays.

  • 12

    Nov

  • 27

    Nov

EIDX Eidos Therapeutics
$12.71

0.34 (2.75%)

08/27/18
JPMS
08/27/18
NO CHANGE
JPMS
Eidos Therapeutics selloff today overdone, says JPMorgan
JPMorgan analyst Anupam Rama views this morning's selloff in shares of Eidos Therapeutics (EIDX) following the data from Pfizer (PFE) as overdone. The stock in early trading is down 33%, or $6.65, to $13.58.
08/27/18
JPMS
08/27/18
NO CHANGE
JPMS
Overweight
JPMorgan views Eidos Therapeutics selloff on Pfizer data as overdone
JPMorgan analyst Anupam Rama views this morning's selloff in shares of Eidos Therapeutics (EIDX) following the data from Pfizer (PFE) as overdone. The stock in early trading is down 33%, or $6.65, to $13.58. The Tafamidis Phase 3 Transthyretin Cardiomyopathy study from Pfizer "leaves plenty of room for mortality improvement" for Eidos Therapeutics' AG10, Rama tells investors in a research note. He believes the weakness in Eidos is overdone based on the totality of the data presented at the ESC Congress and in the New England Journal of Medicine. Eidos has "plenty of catalysts on the horizon" that can help validate AG10, Rama contends. The analyst keeps an Overweight rating on the shares.
10/31/18
ROTH
10/31/18
INITIATION
Target $28
ROTH
Buy
Eidos Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started Eidos Therapeutics with a Buy rating and $28 price target. The analyst notes that the company's Phase 2 results are anticipated at the AHA meeting on November 10, and views AG10 as a best-in-class transthyretin stabilizer for treatment of ATTR-CM.
10/31/18
10/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CVR Energy (CVI) initiated with a Buy at Citi. 2. Cheniere Energy (LNG) reinstated with an Overweight at JPMorgan. 3. Eidos Therapeutics (EIDX) initiated with a Buy at Roth Capital. 4. NV5 Global (NVEE) and GSE Systems (GVP) were initiated with a Buy at Maxim. 5. Nexa Resources (NEXA) initiated with an Outperform at National Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Earnings
Peoples Bancorp reports Q4 EPS 71c, consensus 67c »

Earnings per diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CTSO

CytoSorbents

$7.66

0.04 (0.52%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Hot Stocks
CytoSorbents expands partnership with Fresenius Medical Care to Korea and Mexico »

CytoSorbents announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$60.80

2.57 (4.41%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRNA

Dicerna

$10.76

-0.395 (-3.54%)

07:08
01/22/19
01/22
07:08
01/22/19
07:08
Upgrade
Dicerna rating change  »

Dicerna upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$123.97

1.03 (0.84%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Travelers reports Q4 return on equity 10.9% »

Reports Q4 core return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

, RHHBY

Roche

$0.00

(0.00%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Voyager Therapeutics names Robert Hesslein as general counsel »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 01

    Feb

  • 18

    Mar

CAPR

Capricor Therapeutics

$0.62

-0.007 (-1.11%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Capricor Therapeutics announces outcome of FDA meeting for CAP-1002 »

Capricor Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Breaking Hot Stocks news story on Aurinia Pharmaceuticals »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

REXR

Rexford Industrial

$32.00

0.225 (0.71%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Rexford Industrial acquires two industrial properties for $27.6M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$87.31

-0.29 (-0.33%)

07:06
01/22/19
01/22
07:06
01/22/19
07:06
Hot Stocks
Medtronic announces new data shared on IN.PACT Admiral DCB »

Medtronic announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 18

    May

  • 28

    May

BG

Bunge

$52.95

0.745 (1.43%)

07:06
01/22/19
01/22
07:06
01/22/19
07:06
Hot Stocks
Bunge says Lupo, Bachrach, Boilini won't stand for re-election to board »

As part of Bunge's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:05
01/22/19
01/22
07:05
01/22/19
07:05
Hot Stocks
Aurinia says VOS demonstrates statistically superior efficacy versus Restasis »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

07:05
01/22/19
01/22
07:05
01/22/19
07:05
General news
Global stock markets under pressure after gloomy IMF report. »

Global stock markets…

BG

Bunge

$52.95

0.745 (1.43%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Bunge sees FY18 total segment adjusted EBIT below previously disclosed range »

The company provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPGP

IPG Photonics

$132.54

3.37 (2.61%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
IPG Photonics to acquire Padtec SND »

IPG Photonics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$126.64

1.37 (1.09%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Centene subsidiary selected by Arizona's Department of Corrections »

Centene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 28

    May

QURE

uniQure

$31.29

-0.02 (-0.06%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
uniQure announces FDA clearance of AMT-130 NDA in Huntington's disease »

uniQure N.V. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNCE

Concert Pharmaceuticals

$14.21

-0.065 (-0.46%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Concert completes enrollment of 12 mg cohort in CTP-543 Phase 2a trial »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 30

    Jan

  • 12

    Feb

  • 13

    Feb

RCKT

Rocket Pharmaceuticals

$16.00

0.23 (1.46%)

07:03
01/22/19
01/22
07:03
01/22/19
07:03
Hot Stocks
Rocket Pharmaceuticals announces FDA clearance of IND application for RP-A501 »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTI

Pluristem

$1.12

(0.00%)

07:03
01/22/19
01/22
07:03
01/22/19
07:03
Hot Stocks
Pluristem to collaborate with IDF in treatment of burn injuries »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRY

Tilray

$77.14

-6.17 (-7.41%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Tilray to acquire Natura Naturals for up to C$70M »

Tilray announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$52.95

0.745 (1.43%)

, CAG

Conagra Brands

$21.58

0.34 (1.60%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Bunge names Gregory Heckman as acting CEO »

Bunge (BG) announced that…

BG

Bunge

$52.95

0.745 (1.43%)

CAG

Conagra Brands

$21.58

0.34 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CGEN

Compugen

$3.18

0.07 (2.25%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Compugen announces publication of preclinical data on PVRIG »

Compugen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$110.57

6.4 (6.14%)

07:00
01/22/19
01/22
07:00
01/22/19
07:00
Recommendations
Kansas City Southern analyst commentary  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$123.97

1.03 (0.84%)

06:58
01/22/19
01/22
06:58
01/22/19
06:58
Hot Stocks
Travelers reports Q4 consolidated combined ratio of 97.5% »

Fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.